Get started
Work

Abstract CT125: A phase 1/2 randomized study of IGM-2323 in relapsed/refractory non-Hodgkin lymphomas

Year: 2022
Type: conference-abstract
DOI: 10.1158/1538-7445.am2022-ct125
Authors: Loretta Nastoupil, Elizabeth Budde, Won Seog Kim, Ajay Gopal, Chan Cheah, Ian Flinn, Gareth Gregory, Matthew Matasar, Catherine Diefenbach, Matthew Ku, Sung-Soo Yoon, Ibrahim Qazi, Rachel Wei, Maya Leabman, Genevive Hernandez, Iris Sison, Bruce Keyt, Thomas Manley, Phillipe Armand
Institutions: The University of Texas MD Anderson Cancer Center, City Of Hope National Medical Center, Samsung Medical Center, Seattle Cancer Care Alliance, University of Washington, Fred Hutch Cancer Center, Sir Charles Gairdner Hospital, Sarah Cannon, Tennessee Oncology, Monash Health, Monash University, Memorial Sloan Kettering Cancer Center, NYU Langone Health, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, The University of Melbourne, St Vincent's Hospital Melbourne, Seoul National University, Seoul National University Hospital, IGM Biosciences (United States), Dana-Farber Cancer Institute
Language: English
Field: Medicine
Open Access status: closed
OpenAlex ID: W4282914445
Cites:
Cited by: 1
Related to: 10